Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 2/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25882219 | 0.80 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1SMN1; SMN2SLC6A3DRD2 | |
| SCHEMBL25881984 | 0.80 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1SMN1; SMN2SLC6A3DRD2 | |
| SCHEMBL25882229 | 0.80 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1SMN1; SMN2SLC6A3DRD2 | |
| SCHEMBL25881977 | 0.80 | SIGMAR1 (0.40) | SIGMAR1ALDH1A1SMN1; SMN2SLC6A3DRD2 | |
| SCHEMBL21831029 | 0.79 | SIGMAR1 (0.52) | SIGMAR1SLC6A3KCNH2DRD2DRD3 | |
| SCHEMBL25883376 | 0.79 | SIGMAR1 (0.36) | SIGMAR1ALDH1A1SMN1; SMN2SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL30910967 | 0.78 | SIGMAR1 (0.51) | SIGMAR1SLC6A3KCNH2DRD2DRD3 | |
| SCHEMBL25883366 | 0.76 | SIGMAR1 (0.35) | SIGMAR1ALDH1A1SMN1; SMN2SLC6A3KCNH2 | |
| SCHEMBL25882893 | 0.76 | KDM4E (0.49) | SIGMAR1ALDH1A1SMN1; SMN2KCNH2CACNA1B | |
| SCHEMBL25883237 | 0.74 | DPP8 (0.37) | SIGMAR1ALDH1A1SMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 3220/4885ALDH1A1 3814/4885SMN1; SMN2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.